Year: 2025
Type: article
Abstract: The U.S. Food and Drug Administration (FDA) has recently announced two significant advances in the treatment of major depressive disorder (MDD), a condition affecting millions of adults nationwide. These developments expand therapeutic options for patients who continue to struggle despite standard antidepressant therapy.
Source: Mental Health Weekly
DOI: 10.1002/mhw.34668
Author: Valerie A. Canady
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4416225704
FWCI:
Cites:
Cited by:
Related to: